Osteoporosis  >>  odanacatib (MK-0822)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
odanacatib (MK-0822) / Merck (MSD)
NCT00885170 / 2008-008257-30: A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)

Completed
2a
246
NA
Odanacatib, Placebo, Vitamin D3, Calcium
Merck Sharp & Dohme LLC
Osteoporosis
09/11
09/11
NCT00112437: A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)

Completed
2
399
NA
Odanacatib, MK-0822, Vitamin D3, Calcium Carbonate, Placebo
Merck Sharp & Dohme LLC
Osteoporosis
12/07
01/16
NCT00620113: Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)

Completed
2
287
NA
Odanacatib, MK-0822, Vitamin D3, cholecalciferol, Calcium carbonate, Placebo
Merck Sharp & Dohme LLC
Osteoporosis Postmenopausal
05/09
05/09

Download Options